Systemic Scleroderma Stages and Life Expectancy

Reviewed on 1/9/2023

A man's hands with scleroderma
The five-year survival rate for diffuse cutaneous systemic sclerosis is about 84%, while the five-year survival among patients with limited skin (cutaneous) systemic sclerosis is over 90%.

Scleroderma is a rare autoimmune disease that is a type of systemic connective tissue disease (systemic sclerosis). Scleroderma is characterized by progressive skin and connective tissue tightening and hardening. It may also affect subcutaneous tissue, muscles, and internal organs.

There are five stages of scleroderma symptom development and progression. 

  • Stage 1: Immune system malfunction 
    • Something such as environmental toxins or infections triggers changes to the immune system 
  • Stage 2: Circulating pathogenic factors
    • The altered immune system regularly produces destructive autoantibodies or other disease-causing molecules 
  • Stage 3: Microvascular endothelial damage
    • Autoantibodies or other circulating disease factors either directly or indirectly cause repeated trauma to the layer of cells that line small blood vessels (endothelial layers of the microcapillaries)
  • Stage 4: Fibrosis (thickening/scarring)
    • Repeated trauma to the endothelium triggers the process of scarring
  • Stage 5: Organ damage
    • Scarring affects multiple organ systems, including the skin and internal organs

Five-year survival rates

Systemic sclerosis has the highest mortality rate among systemic autoimmune diseases due to pulmonary hypertension, pulmonary fibrosis (interstitial lung disease), and scleroderma renal crisis.

  • The five-year survival rate (that is, patients who are still alive 5 years following diagnosis) among patients with diffuse cutaneous systemic sclerosis is about 84%.
  • Five-year survival among patients with limited skin (cutaneous) systemic sclerosis is high — over 90%.

What Are Symptoms of Scleroderma?

Generalized symptoms of scleroderma include:

Symptoms of systemic sclerosis may affect many parts of the body, such as: 

How Is Scleroderma Diagnosed?

Scleroderma is diagnosed with a patient history and physical examination. 

Tests used to help with the initial diagnosis or to rule out other conditions may include: 

  • Laboratory testing 
    • Complete blood cell count (CBC)
    • Erythrocyte sedimentation rate (ESR)
    • Serum muscle enzyme levels
    • Serum CXCL4 level
    • N-terminal pro-brain natriuretic peptide
    • Autoantibody assays
  • Testing for gastrointestinal symptoms
    • X-rays of the gastrointestinal tract
    • Gastric emptying study 
    • Colonoscopy 
    • Esophagogastroduodenoscopy with appropriate biopsies
    • Esophageal manometry assessment
  • Testing for heart and lung (cardiopulmonary) symptoms
  • Other studies
    • X-rays of extremities
    • Nail-fold capillary microscopy 

What Is the Treatment for Scleroderma?

There is currently no cure for scleroderma. The goal of treatment is relief of symptoms and management if complications. Patients should be re-evaluated every 3-6 months, depending on disease activity and progression. 

Treatment approaches for scleroderma depend on the stage of the disease. 

Stage 1 treatment may include:

  • Hematopoietic stem cell transplants (HSCT)
  • Immune system regulation 
    • Hydroxychloroquine (Plaquenil)
    • Intravenous immunoglobulin (IVIG)
    • Extracorporeal photopheresis
      • A procedure in which blood is removed from the body, treated with ultraviolet light and drugs that become active when exposed to light, and then returned to the body

Stage 2 treatment may include:

Stage 3 treatment may include:

  • Therapeutic plasma exchange (TPE) 
    • May reduce or prevent endothelial damage and the later fibrotic disease stages

Stage 4 treatment may include:

  • Anti-fibrotic drugs (currently in early testing stages)
    • Pirfenidone (Esbriet)
    • Imatinib mesylate (Gleevec)
    • Connective tissue growth factor inhibitors (CCG-203971)

Stage 5 treatment may include targeted treatments such as:

Health Solutions From Our Sponsors

Reviewed on 1/9/2023
References
Image source: iStock Images

http://emedicine.medscape.com/article/331864-overview

https://sclerodermainfo.org/research/systemic-sclerosis-disease-staging/